Background: We report on the activity of anthracycline-based and high-dose prolonged-infusion ifosfamide chemotherapy in a retrospective series of patients affected by advanced myxofibrosarcoma treated at Istituto Nazionale Tumori in Milan, Italy, and within the Italian Rare Cancer Network (RTR).
Methods: Advanced myxofibrosarcoma patients treated with anthracycline + ifosfamide and high-dose prolonged-infusion ifosfamide as a single agent from November 2001 to December 2016 were retrospectively reviewed. All pathological diagnosis were centrally reviewed by at least two expert pathologists. Response was evaluated by RECIST, and survival functions were computed.
Results: Among 34 advanced myxofibrosarcoma patients, 13 were treated with front-line anthracycline + ifosfamide chemotherapy (male/female = 6/7, median age 54 years, range 33-72). Overall best response was: 4 partial responses, 3 stable diseases and 6 progressive diseases, with a median progression-free survival of 4 months. Twenty-eight patients received second/further line high-dose prolonged-infusion ifosfamide (male/female = 17/11, median age 55 years, range 27-75 years). We observed 10 partial responses, 4 stable diseases and 14 progressive diseases, with a median progression-free survival of 4 months. Median overall survival was 12 months.
Conclusions: This retrospective analysis suggests that the combination of anthracyclines and ifosfamide is active in myxofibrosarcoma. In patients already treated with a combination of anthracyclines and ifosfamide, high-dose prolonged-infusion ifosfamide showed activity as well.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568720 | PMC |
| http://dx.doi.org/10.1186/s13569-017-0082-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Histologic and immunologic factors associated with response to immune checkpoint inhibitors in advanced sarcoma.
Clin Cancer Res
December 2024
Stanford University, Palo Alto, California, United States.
Purpose: To characterize factors associated with response to immune checkpoint inhibitors (ICIs) in advanced sarcoma.
Experimental Design: This is a retrospective study with a cohort of 216 patients with advanced sarcoma treated with ICIs between 2016-2023 at Stanford Health Care. Overall survival (OS), progression free survival (PFS), objective response rates per RECIST criteria (ORR), and reason for ICI discontinuation were analyzed across histologic subtypes, ICI regimens, tumor mutational burden (TMB), and PD-L1 expression.
Precision in Prosthetics: Two Case Reports on Transformative Rehabilitation With Custom Ocular and Orbital Prostheses.
Cureus
October 2024
Department of Prosthodontics and Crown and Bridge, Bhojia Dental College and Hospital, Solan, IND.
The eyes play a crucial role in vision and emotional expression, and their loss can profoundly affect appearance and psychological well-being. Eye loss may result from trauma, tumors, infections, malignancies, or congenital abnormalities. Surgical methods for removing an eye include enucleation, evisceration, and exenteration.
View Article and Find Full Text PDFSurgical resection of advanced intrathoracic tumors through a combination of the hemiclamshell and transmanubrial approaches.
Surg Today
September 2024
Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, 2-15 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Purpose: The hemiclamshell (HCS) approach provides a comprehensive view of the anterior mediastinum, whereas the transmanubrial osteomuscular sparing approach (TMA) allows sufficient exposure of the cervico-thoracic transition. We assessed the effectiveness and the outcomes of the combined HCS plus TMA approach to resect thoracic malignant tumors.
Methods: We reviewed five patients with thoracic malignant tumors invading the thoracic outlet who underwent surgery using an HCS and TMA approach between 2018 and 2021.
A rare presentation of primary cardiac myxofibrosarcoma: Case report and literature review.
Cancer Rep (Hoboken)
April 2024
Department of Radiation Oncology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Background: Primary cardiac myxofibrosarcoma is a rare and aggressive malignancy, with the majority of approaching strategies relying on case reports. This article provides insights into its diagnosis and treatment.
Case Presentation: This paper presents the case of a 40-year-old man with sudden onset hemoptysis, leading to the diagnosis of primary cardiac myxofibrosarcoma.
Solitary fibrous tumor occurring at unusual sites: A clinico-pathological series of 31 cases with emphasis on its wide morphological spectrum.
Pathol Res Pract
March 2024
Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Anatomic Pathology, University of Catania, 95123 Catania, Italy. Electronic address:
Article Synopsis
- - Solitary fibrous tumor (SFT) is a rare tumor that can occur in various locations in adults, with no gender preference, and can present a wide range of morphological appearances.
- - The study examined 31 cases of SFT from diverse sites, including uncommon areas like the thoracic spine, mesorectal tissue, and breast, highlighting the tumor's versatility in location.
- - Notable morphological characteristics observed in the tumors included lipomatous areas, myxoid changes, and features resembling other tumors, which can lead to diagnostic confusion; thus, pathologists need to be vigilant to distinguish SFTs from other neoplasms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!